<DOC>
	<DOCNO>NCT02756845</DOCNO>
	<brief_summary>This phase 1 study evaluate safety intralesional talimogene laherparepvec administration pediatric subject advance non-CNS tumor amenable direct injection</brief_summary>
	<brief_title>Study Talimogene Laherparepvec In Children With Advanced Non CNS Tumors</brief_title>
	<detailed_description>This phase 1 , multicenter , open-label study talimogene laherparepvec pediatric subject advance non-CNS tumor amenable direct injection clinical setting . Talimogene laherparepvec administer intralesional injection approximately 18 36 pediatric subject advance non-CNS tumor . Pediatric subject enrol cohort stratify age baseline herpes simplex virus type-1 ( HSV-1 ) serostatus ( 3 6 subjects/cohort ) . DLT evaluate base 3 6 DLT-evaluable subject cohort The DLT evaluation period 35 day initial administration talimogene laherparepvec .</detailed_description>
	<criteria>Subject 's legally acceptable representative provide informed consent/assent subject legally young provide inform consent/assent subject provide write assent base local regulation and/or guideline prior study specific activities/procedures initiate Male female subject age 0 &lt; 18 year time informed consent/assent Willing submit local HSV1 serostatus within 28 day prior enrollment Histologically cytologically confirm nonCNS solid tumor recur standard therapy standard therapy available Presence measurable nonmeasurable disease Subject must candidate intralesional injection , define one follow At least 1 injectable lesion ≥ 10 mm long diameter Multiple injectable lesion aggregate long diameter ≥ 10 mm Performance status outline protocol Life expectancy &gt; 4 month date enrollment Other Inclusion Criteria May Apply . Diagnosis leukemia , nonHodgkin 's lymphoma , Hodgkin 's disease , hematologic malignancy Radiotherapy bone marrow within 6 week prior enrollment OR within 3 month prior enrollment prior radiotherapy craniospinal axis least 60 % pelvis receive Within 2 week prior enrollment local palliative radiotherapy receive CNS tumor clinically active brain metastasis Primary ocular mucosal melanoma History evidence giant congenital melanocytic nevus , dysplastic nevis syndrome xeroderma pigmentosum History malignancy within past 5 year exception ( ) outline protocol , History evidence active autoimmune disease require systemic treatment , replacement therapy consider form systemic treatment Evidence clinically significant immunosuppression outline protocol Active herpetic skin lesion prior complication herpetic infection Additional Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Non CNS Tumor</keyword>
</DOC>